Patrick holds an MSc in Biochemistry, a PhD in Chemistry of Biomolecules from the University of Toulouse, and an MBA from INSEEC Business School in Paris. His expertise spans drug discovery and development, innovation strategy, strategic alliance management, and entrepreneurship, with over 25 years of experience in the life sciences industry across both private and publicly listed pharmaceutical companies.
He has led R&D and business initiatives across a broad range of therapeutic areas, including oncology, inflammation, respiratory, metabolic and cardiovascular diseases, neurodegenerative disorders, reproductive health, and rare/orphan conditions. Patrick has successfully driven over 20 projects through key scientific, regulatory, and strategic partnership milestones, resulting in several drug candidates advancing to late-stage clinical development.
He has held senior roles at AstraZeneca and MerckSerono, and served as Corporate Development Director for Europe at Crown Bioscience, where he was responsible for licensing, strategic partnerships, and contributed to M&A activities. As CEO, CSO, or CDO of biotech companies including Genkyotex, Epiremed, and Conicmeds, Patrick played a central role in shaping scientific direction, corporate strategy, and fundraising efforts.
Patrick is CEO of LipideRa Therapeutics, a consultant to several biotech companies, and a scientific advisor to venture capital firms and technology transfer offices. He is also a co-author on over 20 patents. Patrick is driven by a passion for innovation that improves health, the challenge of building high-performing teams, and the opportunity to translate cutting-edge science into successful, impactful businesses.
